Tag: Durvalumab

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors

June 7, 2023 6:55 am

Key Points:

  • Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
  • T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
… Read more

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

June 3, 2023 7:02 am

Key takeaways:

  • Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
  • The relative contribution of durvalumab requires further study.

 

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more

Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations

April 5, 2023 4:55 pm

by Nichole Tucker

The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more